Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven B Deitelzweig

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Journal of Thrombosis and Thrombolysis|July 27, 2010
Venous thromboembolism in the US: does race matter?Steven B Deitelzweig, Jay Lin, Barbara H Johnson, et al.
The Annals of Pharmacotherapy|March 18, 2003
Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patientsSteven B Deitelzweig, Gordon J Vanscoy, Cynthia S Niccolai, et al.
Advances in Therapy|July 24, 2020
Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USASteven B Deitelzweig, Belinda Lovelace, Mary Christoph, et al.
Clinical Therapeutics|October 1, 2013
Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care populationSteven B Deitelzweig, Brett Pinsky, Erin Buysman, et al.
Clinical Therapeutics|July 23, 2013
Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care populationSteven B Deitelzweig, Erin Buysman, Brett Pinsky, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 1, 2017
Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United StatesSteven B Deitelzweig, Michael Evans, Jeffrey Trocio, et al.
Hospital Practice (1995)|September 2, 2011
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndromeMachaon Bonafede, Yonghua Jing, Joette Gdovin Bergeson, et al.
Journal of Medical Economics|October 15, 2020
Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulantsGregory J Fermann, Belinda Lovelace, Mary J Christoph, et al.
Thrombosis Research|December 5, 2022
Healthcare utilization differences between an apixaban-based and warfarin-based strategy for acute venous thromboembolism in patients with end-stage kidney diseaseShirin Ardeshirrouhanifard, Michael I Ellenbogen, Jodi B Segal, et al.
Hospital Practice (1995)|November 12, 2010
Prevalence of stroke/transient ischemic attack among patients with acute coronary syndromes in a real-world settingSteven B Deitelzweig, Augustina Ogbonnaya, Karina Berenson, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Thrombosis and Thrombolysis|July 27, 2010
Venous thromboembolism in the US: does race matter?Steven B Deitelzweig, Jay Lin, Barbara H Johnson, et al.
The Annals of Pharmacotherapy|March 18, 2003
Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patientsSteven B Deitelzweig, Gordon J Vanscoy, Cynthia S Niccolai, et al.
Advances in Therapy|July 24, 2020
Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USASteven B Deitelzweig, Belinda Lovelace, Mary Christoph, et al.
Clinical Therapeutics|October 1, 2013
Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care populationSteven B Deitelzweig, Brett Pinsky, Erin Buysman, et al.
Clinical Therapeutics|July 23, 2013
Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care populationSteven B Deitelzweig, Erin Buysman, Brett Pinsky, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 1, 2017
Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United StatesSteven B Deitelzweig, Michael Evans, Jeffrey Trocio, et al.
Hospital Practice (1995)|September 2, 2011
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndromeMachaon Bonafede, Yonghua Jing, Joette Gdovin Bergeson, et al.
Journal of Medical Economics|October 15, 2020
Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulantsGregory J Fermann, Belinda Lovelace, Mary J Christoph, et al.
Thrombosis Research|December 5, 2022
Healthcare utilization differences between an apixaban-based and warfarin-based strategy for acute venous thromboembolism in patients with end-stage kidney diseaseShirin Ardeshirrouhanifard, Michael I Ellenbogen, Jodi B Segal, et al.
Hospital Practice (1995)|November 12, 2010
Prevalence of stroke/transient ischemic attack among patients with acute coronary syndromes in a real-world settingSteven B Deitelzweig, Augustina Ogbonnaya, Karina Berenson, et al.
Pageof 3